Identificaiton of Non‐Alcoholic Steatohepatitis (NASH) Using Plasma Metabolome in Humans
نویسندگان
چکیده
منابع مشابه
Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
BACKGROUND The changes in the liver in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However it has remained difficult to differentiate between NASH and non-progressive NAFLD on the basis of the clinical findings alone. AIMS In this study we investigated the clinical usefulness of plasma Pentraxin3 (PTX3) levels to pre...
متن کاملNoninvasive evaluation of nonalcoholic steatohepatitis (NASH).
Sir Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of conditions, ranging from a simple fatty liver to non-alcoholic steatohepatitis (NASH) with or without fibrosis, to cirrhosis and its complications (1). It is important to distinguish NASH from simple fatty liver because NASH patients are in greater risk of developing cirrhosis, liver failure and hepatocellular carcinom...
متن کاملNonalcoholic Steatohepatitis (NASH) — Symptoms and Treatment
Non-alcoholic steatohepatitis, one form of the non-alcoholic fatty liver disease spectrum, has been associated with obesity and lipid dysregulation. The patient usually presents with abnormal lipid and liver profiles. The most evidence based treatment for non-alcoholic steatohepatitis involves around weight loss, glycemic control and avoiding liver insulting drugs. Our current understanding of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The FASEB Journal
سال: 2008
ISSN: 0892-6638,1530-6860
DOI: 10.1096/fasebj.22.1_supplement.1162.5